AMLX

Amylyx Pharmaceuticals, Inc. [AMLX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

AMLX Stock Summary

Top 10 Correlated ETFs

AMLX

Top 10 Correlated Stocks

AMLX

In the News

AMLX Financial details

Company Rating
-
Market Cap
142.34M
Income
49.27M
Revenue
380.79M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
384
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
602.18
Forward P/E
-
PEG
-48.32
P/S
3.76
P/B
2.64
P/C
-
P/FCF
-20.95
Quick Ratio
8.43
Current Ratio
9.52
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.73
EPS next Y
-
EPS next Q
-
EPS this Y
-124.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
205.71%
Revenue Q/Q
5.61%
EPS Q/Q
-77.35%
-
-
-
-
SMA20
15.48%
SMA50
3.61%
SMA100
-27.71%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-0.02%
Gross Margin
94%
Oper. Margin
-3%
Profit Margin
1%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.07-31.77
52W High
-88.19%
52W Low
+83%
RSI
50.65
Rel Volume
0.16
Avg Volume
3.14M
Volume
515.39K
Perf Week
0.27%
Perf Month
1.95%
Perf Quarter
24.49%
Perf Half Y
18.83%
-
-
-
-
Beta
-0.93
-
-
Volatility
0.07%, 0.28%
Prev Close
-5.43%
Price
3.66
Change
-3.17%

Something similar

Top by Market Cap
MIX.JO
NVD.DE
LLY.SW
3V64.DE
META
Top Correlated ETFs
INMU.L
EIMT.MI
BCIM
DSB.PA
3UBS.MI
Top Correlated Stocks
CLIQ.DE
VRLA.PA
GSL
0220.HK
ERII
Similar Market Cap
ARBK
PRPL
TPBAU
HNU.TO
EMF

Company Profile

Healthcare Biotechnology
  • Volume Average 3.14M
  • Market Capitalization 142.34M
  • Employee 384
  • CEO Mr. Joshua B. Cohen
  • Headquarters Cambridge,MA,US
  • IPO Date 2022-01-07
  • Website https://amylyx.com

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.